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ABSTRACT: The bioavailability of insoluble crystalline active pharmaceutical ingredients (APIs) can be enhanced by formulation 
as amorphous solid dispersions (ASDs). One of the key factors of ASD stabilisation is the formation of drug - polymer interactions at 
the molecular level. Here, we used a range of multidimensional and multinuclear nuclear magnetic resonance (NMR) experiments to 
identify these interactions in amorphous acetaminophen (paracetamol)/ hydroxypropylmethylcellulose acetyl succinate (HPMC-AS) 
ASDs at various drug loadings. At low drug loading (< 20% wt.), we showed that 1H-13C through-space heteronuclear correlation 
experiments identify proximity between aromatic protons in acetaminophen with cellulose backbone protons in HPMC-AS. We also 
show that 14N-1H heteronuclear multiple quantum coherence (HMQC) experiments are a powerful approach in probing spatial in-
teractions in amorphous materials and establish the presence of hydrogen bonds (H-bond) between the amide nitrogen of aceta-
minophen with the cellulose ring methyl protons in these ASDs. In contrast, at higher drug loading (40% wt.), no acetaminophen – 
HPMC-AS spatial proximity was identified and domains of recrystallisation of amorphous acetaminophen into its crystalline form I, 
the most thermodynamically stable polymorph, and form II are identified. These results provide atomic scale understanding of the 
interactions in the acetaminophen / HPMC-AS ASD occurring via H-bond interactions.  
KEYWORDS: Acetaminophen (paracetamol), Hydroxypropylmethylcellulose acetyl succinate (HPMC-AS), Amorphous solid disper-
sion, Solid-state NMR, Drug-polymer interactions, Multidimensional NMR.
1 Introduction 
Biopharmaceutical Class II active pharmaceutical ingredients 
(APIs) (or drugs) exhibit poor bioavailability as a result of low 
aqueous solubility, accompanied by high biological membrane 
permeability.1 API can exist either in the crystalline form, 
characterised by a three-dimensional structure in which 
molecules are packed in a regularly ordered repeating pattern, 
or amorphous form defined as an ensemble of molecules/units 
arranged randomly. The energy barrier required to break 
down the long-range structure means that crystalline systems 
can show low solubility, and a low kinetic rate of dissolution. In 
amorphous systems the lack of long range order greatly 
enhances the apparent solubility and rate of dissolution.2 From 
a thermodynamic view point, the crystalline state is low energy 
and stable in contrast to the amorphous state which is marked 
as high energy and unstable. The metastable nature of the 
amorphous state leads to the likelihood of physical instability 
and recrystallisation promoted by external factors such as 
temperature or humidity.3 Converting crystalline drugs to their 
amorphous counterpart is one of the most promising 
approaches in pharmaceutical material sciences in order to 
enhance APIs solubility and bioavailability. This strategy can be 
adopted only as long as a supersaturated solution of 
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amorphous API can be maintained in the aqueous medium over 
time.4  
Amorphous solid dispersions (ASDs) have been extensively 
used to stabilise supersaturated solution of APIs, resulting in a 
general increase of the oral bioavailability of poorly soluble 
drugs.5–7 An ASD can be defined as a dispersion of one or more 
APIs in a solid-state inert carrier, usually an amorphous 
polymer,8 and can be prepared by a range of manufacturing 
processes,9 including spray drying10, spray freeze drying11, and 
hot melt extrusion12. Polymers such as polyethylene glycol 
(PEG),13 and polyethylene oxide (PEO),14 polyvinylpyrrolidone 
(PVP),15 polyvinylpyrrolidone-polyvinyl acetate (PVP-VA),16 
hydroxypropylmethylcellulose (HMPC),17 and 
hydroxypropylmethylcellulose acetyl succinate (HPMC-AS)18 
have been successfully used in ASDs. In particular, HPMC-AS 
has recently been suggested as a promising solid matrix to 
formulate ASDs19 due to its high glass transition temperature, 
Tg, in the order of 120 °C,20 its amphiphilic nature arising from 
the existence of hydrophilic (e.g., acetyl, A) and hydrophobic 
(e.g., succinoyl, S) functional groups, and the capability to tune 
the A and S contents. 
It has been demonstrated that the polymer in ASDs plays a 
crucial role in stabilising the amorphous form of the drug.21 The 
choice of a suitable polymer to formulate a specific dispersion 
largely depends on several chemical-physical properties such 
as Tg, thermal stability, dissolution profile, performance in 
dissolving API, and capability to stabilise amorphous drug.22 
These characteristics contribute to the stabilisation of the ASD 
which is due to the polymer’s anti-plasticising effect, reducing 
molecular mobility of the amorphous API, and the formation of 
specific API - polymer interactions.21 Intermolecular 
interactions such as hydrogen-bonding (H-bond), ionic forces, 
π-π, or electrostatic interactions are well established as the 
most significant interactions capable of stabilising such 
dispersed systems4 by inhibiting recrystallisation phenomena 
in amorphous matrix and preventing competitive API - API or 
polymer - polymer intramolecular interactions. Recently 
HPMC-AS polymer23 has been widely used to prepare ASD due 
its remarkable ability in stabilising amorphous dispersions 
arising from the formation of strong API - HPMC-AS 
interactions.24  
The elucidation of the nature of the interaction between drugs 
and polymers and detecting recrystallised drugs in ASDs 
constitute some of the most significant challenges in 
pharmaceutical material sciences and require the exploitation 
of a range of characterisation approaches, often combining 
powder X-ray diffraction (PXRD), thermal analysis, vibrational 
methods and solid-state nuclear magnetic resonance (NMR) 
spectroscopy.25,26 The PXRD patterns of amorphous solids 
result in broad diffuse scattering signals due to the lack of long-
range order. Nevertheless, PXRD methods can provide 
significantly useful information on the residual crystalline 
content in ASDs, for example during stability studies.27 
Thermal analysis, including differential scanning calorimetry 
(DSC) and temperature-modulated DSC (mDSC),28 have been 
employed to estimate the residual crystallinity in amorphous 
systems29 and are often used to determine Tg values and detect 
thermal events revealing crystallisation and melting 
phenomena.30 DSC therefore allows to detect miscibility of 
individual components of an ASD, where the observation of a 
single Tg indicates miscibility between API and polymer.31 The 
Gordon-Taylor’s (GT) model32 can be used to estimate the Tg of 
an ideal binary mixture (Tgmix) with significant deviations 
between predicted Tgmix and experimentally determined Tg 
providing useful information about the interactions between 
the components in the mixture,4,25,26 as the presence of API-API 
or API-polymer interactions can affect the Tg value of the 
system, while agreement suggests systems with absence of 
specific drug-polymer interactions. Furthermore, access to ASD 
stability can be also obtained using thermodynamic modelling 
and short to medium term physical stability of several API-
polymer blend ASDs, including acetaminophen – HPMC-AS 
dispersions under controlled temperature and relative 
humidity (RH) conditions, have been determined for the 20 and 
40% wt. formulation to be up to 6 and 1 month(s), 
respectively.33 This work highlights a reduction of stability of 
these systems with the increase of the polymer content and an 
increase of RH. 
A range of analytical methods including vibrational, Raman, 
Fourier-transform infrared spectroscopy (FT-IR) and solid-
state nuclear magnetic resonance (NMR) spectroscopies have 
been used to provide atomic scale information about solid 
dispersions. Raman applications include the measurements of 
crystallisation rate34 and mapping solid dispersions to identify 
and discriminate crystalline/amorphous domains.35 FT-IR 
methods can be used to probe H-bonds for specific functional 
groups including hydroxyl, amino, and carbonyl groups when 
present in the API and/or the polymer molecular structure.36 It 
has been demonstrated that when those functional groups are 
involving in H-bonding interactions, a simultaneous decrease 
in the stretching frequency and a widening of their absorption 
bands are observed due to smaller intermolecular distance 
between the donor-acceptor groups.37 
NMR spectroscopy has proved itself as a powerful technique by 
providing an invaluable source of both structural and dynamics 
information at the atomic scale thereby being demonstrated as 
one of the most powerful method of characterisation. In 
particular, in the field of pharmaceutical sciences,38,39 NMR 
allows the determination of the structure of drugs40 and 
polymers.41 Recently, NMR has emerged as a robust approach 
in (pharmaceutical) amorphous dispersions to identity site-
specific API - polymer intermolecular interactions from 
changes in chemical shift values.42–45 For example, using one 
dimensional (1D) and two dimensional (2D) NMR experiments, 
electrostatic interactions and H-bonding were identified in 
amorphous posaconazole (POSA) dispersion in HPMC-AS and 
involved the POSA's triazole and difluorophenyl ring moieties 
with some of the HPMC-AS's substituent groups.44 The 
presence of π-π aromatic packing interaction between POSA 
and HPMC-phthalate (HPMC-P) amorphous dispersion have 
also been highlighted.44 Drug-polymer interactions in 
carbamazepine (CBZ) in HPMC, HPMC-A, and HPMC-S 
dispersions have also been established42 and identified H-
bonding between the CBZ's -NH2 group with the acetyl moiety 
in HPMC-A, and between both CBZ -NH2’s and carbonyl groups 
of the succinyl group in HPMC-S. This demonstrates the 
important role that both acetyl and succinyl groups of HPMC-
AS could play in the formation of stable API-polymer 
connections. 2D NMR techniques that include homonuclear and 
heteronuclear correlation spectroscopy are widely used to 
detect intramolecular interaction by exploiting the homo- and 
heteronuclear through space dipolar coupling between the 
nuclei. In order to increase the NMR sensitivity and hence to 
have access to high-resolution spectra and enabling proton 
detection, the use of ultrafast Magic Angle Spinning (MAS) 
experiments, with frequency in the 50 - 110 kHz range, have 
also recently emerged. They enable fast characterisation of 
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pharmaceutical compounds and how they formulate by 
probing API-polymer interaction,45 allowing NMR 
crystallography approaches46 and understanding of low drug 
loaded formulation.47 The 14N-1H heteronuclear multiple-
quantum coherence (HMQC)48 experiment carried out at high 
magnetic field and at ultrafast MAS conditions under direct 1H 
signal detection has been robustly employed to probe 
interactions in crystalline systems49,50 and recently to highlight 
molecular association and interactions in amorphous 
dispersions.51,52 14N-1H HMQC spectra were used to identify 
hydrogen bonding interaction in a nicotinamide palmitic acid 
cocrystal and acetaminophen - PVP amorphous dispersion.50 
The versatility of this experiment was demonstrated by 
providing information on the symmetry of the nitrogen 
environment and through-space proximities in paclitaxel 
loaded polymer micelles amorphous formulations.52 The 14N-
1H HMQC experiment has however, to the best of our 
knowledge, not been used so far to investigate API-polymer 
interactions in HPMC-AS based amorphous formulations. 
Here, we report the stability of amorphous acetaminophen in 
HPMC-AS ASDs at different drug loadings by identifying the 
presence of drug-polymer intramolecular interactions with 
multinuclear multidimensional NMR experiments. 
Acetaminophen (Figure 1, and supporting information Figure 
SI-1) is one of the most widely used API and its chemical-
physical data, including melting point and solubility profiles, as 
well as crystalline data,53,54 NMR spectra,55 are largely known. 
HPMC-AS polymer was chosen as excipient due to its excellent 
capacity to stabilise amorphous dispersion.42,44. Morevoer, the 
lack of overlap between acetaminophen and polymer signals in 
the 13C NMR spectra allows monitoring of the changes in 
chemical shift and line width of the signals of both components 
in order to establish API-polymer interactions and 
crystalline/amorphous behavior. Multidimensional 
multinuclear MAS NMR data enable access to structural 
information in the solid state, highlighting the presence of API 
- polymer intermolecular interactions for ASDs with drug 
loading < 20% wt. and providing useful indications of their 
stability. The approach also suggests the absence of API - 
polymer intermolecular interaction in the 40% wt. ASD and 
rather identifies signals corresponding to crystalline 
acetaminophen interacting with itself. 
 
Figure 1. Chemical structure of (a) acetaminophen and (b) 
HPMC-AS polymer. HPMC-AS consists of a cellulose ring 
bonded with various R groups that include hydrogen, methyl 
(M), hydroxypropyl (P), acetyl (A), and succinoyl (S) groups. 
The wavy bond in the cellulose ring indicates that cellulose ring 
can exist in two different cyclic hemiacetal configurations, 
called α- and β- glucopyranose, distinguishable from the differ-
ent configurations of the anomeric carbon C1. The lettering and 






2 Experimental section  
2.1 Materials 
ASDs were prepared using acetaminophen form I (99.5 %) 
purchased from Spectrum Chemical Company and HPMC-AS 
polymer M grade obtained from Shin-Etsu Chemical Co. (lot # 
6033060, M content = 23.4 %, P content = 7.3%, A content = 
8.8%, and S content = 11.2%). Sigma-Aldrich’s acetaminophen 
form I was used to carried out the PXRD analysis. The dipeptide 
β-AspAla was obtained from Bachem. All materials were used 
as received. 
2.2 Synthesis of ASDs 
General procedure of the preparation of ASDs: Gram-scale 
batches formulated at 10, 20 and 40%, wt. of acetaminophen 
were manufactured using a custom-built small-scale spray 
dryer. Spray dry solution of acetaminophen and polymer 
containing 2.5% solid (acetaminophen and HPMC-AS) were 
sprayed at 65-70 oC from acetone (80 mL) using heated 
nitrogen gas through a two-fluid spraying nozzle (2050 
LC/64AC, Spraying Systems Co). The ASD was then collected by 
filtration from the spray dryer and dried overnight in vacuo. 
ASDs were stored in a freezer kept at low temperature (-80 °C) 
to prevent API recrystallisation.  
Synthesis of 10% wt. acetaminophen in HPMC-AS ASD: This 
formulation was prepared according to the general procedure 
highlighted above using acetaminophen (0.2 g, 1.3 mmol) and 
HPMC-AS (1.7 g). 
Synthesis of 20% wt. acetaminophen in HPMC-AS ASD: This 
formulation was prepared according to the general procedure 
highlighted above using acetaminophen (0.4 g, 2.7 mmol) and 
HPMC-AS (1.6 g). 
Synthesis of 40% wt. acetaminophen in HPMC-AS ASD: This 
formulation was prepared according to the general procedure 
highlighted above using acetaminophen (0.8 g. 5.3 mmol) and 
HPMC-AS (1.2 g). 
2.3 PXRD measurements 
Laboratory PXRD data were collected using a PANalytical 
Empyrean diffractometer equipped with a high throughput 
Transmission geometry, focusing mirror, 1/2 degree 
divergence, and anti-scatter slits, 4 mm beam mask, 0.04-
degree soller slits, with Cu-Kα of 1.541874 Å. PXRD patterns 
were measured over the 2θ range 2−40° over 1 hour. 
2.4 Standard and modulated DSC measurements 
DSC experiments were performed using a DSC Q1000 (TA 
Instruments, DE, USA) system using TA-Tzero aluminium pans 
loaded with an amount of around 10 mg of sample. Standard 
DSC analyses were carried out using a cool-heat-cool cycle 
method in which the sample was cooled to -15 °C and heated 
up to 160 °C with a ramp of 10 °C/min, and then after an 
isotherm of 5 min, a cool ramp of 20 °C/min was applied back 
down to -15 °C. mDSC experiments were carried out using a 
heating ramp of 2.5 °C/min with a modulation amplitude of 1.5 
°C every 60 s. 
2.5 Solid State NMR experiments 
1H NMR spectra were recorded on a Bruker 800 MHz (18.8 T) 
Avance Neo NMR spectrometer using a Bruker 1.3 mm HX MAS 
probe or on a Bruker 850 MHz (20 T) Avance Neo spectrometer 
equipped with 1.3 mm triple-resonance HXY MAS probe in 
double resonance (DR) mode. All the spectra were recorded 
under a MAS frequency of νr = 60 kHz. 1H pulses were carried 
out at a radio frequency (rf) field magnitude of 100 kHz. ASDs 
1H spin-lattice relaxation times T1 were recorded at 18.8 T from 
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saturation recovery experiments and fitted to a stretch 
exponential function 1-exp[-(τ/T1)α] in which τ is the variable 
delay and α the stretch factor ranging from 0.5 and 1.  
All 13C/15N cross polarisation (CP) and two-dimensional 2D 1H-
13C/15N CP heteronuclear correlation (HECTOR) experiments 
were performed on a Bruker 400 MHz (9.4 T) Avance III HD 
NMR spectrometer equipped with a 4 mm triple-resonance 
HXY MAS probe in DR mode tuned to 1H and 13C or 15N at 
Larmor frequencies of 400.1, 100.6 and 40.5 MHz, respectively. 
1H pulses and SPINAL-64 heteronuclear decoupling56 during 
13C/15N detection were carried out with rf field amplitude of 83 
kHz. All experiments were performed under a MAS frequency 
of νr = 12.5 kHz for 13C and 10 kHz for 15N and using a recycle 
delay of 1.3 x 1H T1s obtained as above (data at 9.4 T not given). 
The Hartmann-Hahn57 conditions for 13C CP were achieved 
using a 13C rf amplitude of around 45 kHz ramped to obtain 
maximum signal at a 1H rf field of 60 kHz, and for 15N CP, a 15N 
rf amplitude of 28 kHz ramped to obtain maximum signal at a 
1H rf field of 50 kHz was used. A 2 ms contact time during 13C 
CP and optimised CP contact times of 1 ms for amorphous 
material and 6 ms for crystalline sample during 15N CP were 
used. ASDs 1H spin-lattice relaxation times in the rotating 
frame (T1ρ) were obtained at 9.4 T, using a spin-lock pulse 
sequence through 13C detection via CP, at 1H frequencies of 
ω1/2π of 40 and 83 kHz and fitted to a stretch exponential 
function of the form exp[-(τ/T1ρ)β] (with β ranging between 0.2 
to 1). 13C T1s were obtained at 9.4 T from 13C inversion recovery 
via CP experiments and fitted to an expression of the form exp[-
(τ/T1)γ] (with γ ranging from 0.4 to 1). Frequency switched 
Lee-Goldberg (FSLG) homonuclear decoupling58 during the 1H 
t1 evolution time in the 2D CP HETCOR spectra was obtained at 
a rf amplitude of 83 kHz and an offset of 60 kHz. Experimentally 
determined 1H scaling factors λexp for FSLG (as measured on L-
alanine using the experimental conditions given above) were 
used to recover the full 1H chemical shifts δ(1H)MAS from the 
scaled down apparent chemical shifts δ(1H)APP according to 
δ(1H)APP = λexpδ(1H)MAS that result from this decoupling. 
14N-1H HMQC experiments were carried out using a Bruker 800 
MHz (18.8 T) Avance Neo NMR spectrometer equipped with a 
Bruker 1.3 mm HX MAS probe tuned to 1H and 14N at 800.3 and 
58.7 MHz, respectively, or using a Bruker 850 MHz (20.0 T) 
Avance Neo NMR spectrometer equipped with a 1.3 mm triple 
resonance HXY MAS probe operating in DR mode tuned to 1H 
and 14N at 850.2 and 61.4 MHz, respectively. Experiments were 
performed under a MAS frequency νr = 60 kHz. In the 14N-1H 
HMQC pulse sequence used, heteronuclear dipolar couplings 
were reintroduced via rotary resonance recoupling, R3,59 on the 
n = 2 resonance condition,48 using an x, -x phase inversion60 of 
individual block lengths of one rotor period of 16.7 μs at rf 
amplitude of 120 kHz (2 x MAS frequency). 1H and 14N pulses 
were performed at rf amplitude of 100 and 72 kHz, 
respectively. HMQC spectra were processed after removal of 
the first few points in the free-induction-decay (FID) using a 
home-built macro running on TopSpin to reduce baseline 
distortion and residual t1 noise from the spectrum. 
1H, 13C and 15N spectra were externally referenced to the NH 
proton of the dipeptide β-AspAla at 8.0 ppm,50 the tertiary 
carbon of adamantane at 29.45 ppm,61 and to glycine at -347.2 
ppm,62 respectively. 14N shifts were referenced to solid NH4Cl 
at -341.3 ppm62 which has a cubic 14N site.63 Magic angle 
calibrations were achieved by maximising either the 
separation of NH3 and NH resonances of the dipeptide β-AspAla 
in the 14N-1H HMQC spectrum or the number of rotational 
resonances in the time domain of the 79Br spectrum of KBr. The 
errors associated with 1H, 13C, 15N chemical shifts and 14N 
parameters are given in the respective tables. 1H T1ρ and 13C T1 
fitting data were carried out using MATLAB R2017a. 
Deconvolution of the experimental spectra was carried out in 
TopSpin 4.0.5 using the solid line shape analysis routine.  
3 Results and discussion 
3.1 PXRD characterization 
Acetaminophen exists in three polymorphic forms:53,64,65 
monoclinic form I (space group P21/a, and number of 
asymmetric unit in the cell, Z’ = 1) which is the most 
thermodynamically stable form; orthorhombic form II (space 
group Pcab, Z’ = 1) polymorph, and a highly metastable form III 
(space group Pca21, Z’ = 2). Time-dependent PXRD patterns 
measurements (Figure 2) on acetaminophen – HPMC-AS ASDs 
at 10% wt. (in dark blue), 20% wt. (in orange) and 40% wt. (in  
 
 
Figure 2. PXRD patterns of (a) simulated acetaminophen form 
I from CSD (refcode HXACAN01, brown dotted lines)64, (b) ex-
perimental acetaminophen form I (brown full lines), and (c) 
simulated acetaminophen form II from CSD (refcode 
HXACAN23, light blue dotted lines)64. Comparison of XRD pat-
terns of 10% wt. (dark blue), 20% wt. (orange) and 40% wt. 
(red) for the acetaminophen – HPMC-AS ASDs at times of (d) 
less than 1 day, (e) 1 week, (f) 4 weeks, and (g) 1 year at RT 
(around 20 °C) and ambient RH (ranging from 30 to 50%). Af-
ter 1 year, the 10% wt. ASD still shows an amorphous state 
while, in the 20% wt. traces of recrystallisation to acetamino-
phen l is observed and further confirmed by the 13C CP HETCOR 
spectra (Figure SI-2). In 40% wt. ASD, acetaminophen forms I 
and II are detected after only 1 week. 
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red) loadings were carried out over a one-year period of 
exposure at room temperature (RT, around 20 °C) and ambient 
relative humidity (RH, ranging from 30 to 50%) to monitor the 
chemical stability of the systems and potential recrystallisation 
phenomena. The diffraction patterns of the 10% wt. (in dark 
blue) ASD exhibit the typical broad signal of an amorphous 
material and the absence of Bragg peaks up to 1 year, indicating 
a strong tendency of this system to remain in the amorphous 
state. The 20% wt. ASD shows a typical broad signal of an 
amorphous material only up to 4 weeks at RT and ambient RH 
after which reflections from acetaminophen form I start to 
appear. This is in sharp contrast with the PXRD data in 40% wt. 
ASD that shows recrystallisation after only 1 week and, 
interestingly, to a mixture of both acetaminophen form I and II 
polymorphs 
3.2 Thermal characterization 
The GT model was used to estimate the predicted Tgmix values 
of the acetaminophen – HPMC-AS dispersion at different drug 








where w and Tg are the weight fractions and glass transition 
temperature of each components, respectively, and k a 
constant related to the density ρ (ρacetaminophen = 1.29 gcm-3, 











= 0.8 (2) 
 
Supporting information Table SI-1 summarises Tgs for the 
individual components as well as the predicted and 
experimental Tgmix values obtained for the 10% wt., 20% wt., 
and 40% wt. ASDs with negative deviations from predicted Tgs  
represented in Figure 3. This demonstrates non ideal drug-
polymer mixture,7 the negative deviations suggesting that 
intramolecular  interactions between like species (drug-drug 
or polymer-polymer) dominate, however, importantly, not 
excluding the presence, to a lesser extent, of intramolecular 
drug-polymer interactions (see below).66 Additionally, 
negative deviations can also be interpreted as being indicative 
of non-ideal additivity of volume for the two components and 
points out of a likelihood of phase separation of the system.67 
The largest deviation is found for the 40% wt. solid dispersion 
and suggests that at, amongst the ASDs studied, 
recrystallisation phenomena and phase separation occur more 
quickly in this formulation. 
  
 
Figure 3. Tg values of acetaminophen – HPMC-AS dispersions 
obtained at different acetaminophen loading in HPMC-AS pol-
ymer based ASDs. Experimentally obtained values for the 
ASDs, individual components and predicted values from the GT 
model based on equation 1 are given in empty circles (○), filled 
circles (•) and solid line, respectively. 
3.3 Solid-State NMR data 
Figure 4(a) compares the 13C CP MAS spectra of acetaminophen 
form I, HPMC-AS polymer, 10% wt., 20% wt., and, 40% wt. 
ASDs. The spectrum of acetaminophen form I presents 
resonances at around 170 ppm for the carbonyl (CbI), 152-116 
ppm for the aromatic carbons (CfI, CcI, CdI, CeI) and 24 ppm for 
the methyl carbon (CaI) (see Figure 1(a) and Table SI-2) (‘I’ 
indicates characteristic resonances for the acetaminophen 
form I) based on previous literature.68 The four peaks in the 
region 105 - 60 ppm in the spectrum of HPMC-AS polymer 
(Figure 1(b)) can be attributed to the anomeric C1, C4, C2,3, and 
C5,10 carbons while the shoulders at around 70 and 58 ppm 
correspond to C6,9 (CH2s) and C8 (methoxy group), and the 
three peaks in the aliphatic region to C16,17 (CH2 of the S group), 
C14 (CH3 of the A group), and C11 (methyl group of the P moiety),  
 
 
Table 1. Selected significant changes in 13C chemical shifts. A comprehensive list of 13C chemical shifts is given in 
Table SI-2.a  
Signal Acetaminophen form I HPMC-AS 10% wt. ASD 20% wt. ASD 40% wt. ASD Recrystallised 40% wt. ASD 
C15,18 n.a. 174 174 177 176 174.9 
C13 n.a. 171 172 173 173 172.4 
Cb 169.7 n.a. 171 171 171 169.8(I/II) 
Cf 152.2 n.a. 154 154 154 153.8(II), 152.2(I) 
Cc 132.9 n.a. 131 131 131 132.9(I), 130.76(II) 
Cd 123.3, 120.5 n.a. 121 121 121 123.3(I), 120.5(I/II) 
Ce 116.3, 115.6 n.a. 116 116 116 118.3(II), 115.7(I) 
a Values are given in ppm. The 13C chemical shifts of all assigned resonances are quoted within an accuracy of ± 1 ppm due 
to the broad line widths associated with amorphous samples, except for the crystalline species where they are quoted at 





Figure 4. (a) 13C CP MAS spectra of crystalline acetaminophen form I (brown), HPMC-AS (black),69 10% wt. (dark blue), 20% wt. 
(orange), and 40% wt. acetaminophen – HPMC-AS ASDs (red) recorded at less than 1 day at RT/ambient RH. (b) Magnified view of 
the 190-160 ppm (carbonyl region) of all the spectra. (c) 13C CP spectrum of the 40% wt. dispersion towards recrystallisation after 
1 week at RT/ambient RH. A magnified view of this spectrum is given in the aromatic region is given in Figure SI-3. For spectral 
identification, simulated spectra (dashed grey lines) and spectral deconvolution (grey lines) are also shown. The notations ‘I’ and ‘II’ 
indicate the characteristic resonances for the acetaminophen forms I and II, respectively while the notation ‘a’ indicates resonance 
that can be attributed to amorphous acetaminophen.  
respectively. Deconvolution in the carbonyl region of the 
HPMC-AS polymer reveals two signals assigned to C15,18 (most 
shifted peak, S substituent the COs) and C13 (A's CO).69 The 
knowledge of the 13C assignment of both drug and HPMC-AS 
polymer plays an important role in the identification of drug-
polymer interactions in ASDs as this is largely based on change 
in chemical shifts.4,43 The 13C assignments for the 13C CP MAS 
NMR spectra of all ASDs, recorded at less than 1 day at 
RT/ambient RH, are based on the known spectra of HPMC-AS69 
and acetaminophen form I68 (Table SI-2). In the spectra of the 
ASDs, signals assignable to the amorphous acetaminophen 
generally appear broader than in the crystalline form as 
expected from amorphisation as the loss of crystallinity brings 
of a range of chemical environments present that are randomly 
distributed in the sample resulting in severe inhomogeneous 
line broadening.43 The decreased resolution is evident from of 
the absence of split signals of the aromatic carbons of 
acetaminophen (CdI and CeI), due to the lack of crystal packing, 
indicating the presence of amorphous acetaminophen. This is 
further confirmed by a significant shortening of 13C T1 values 
by up to two orders of magnitude from acetaminophen form I 
to the amorphous acetaminophen in the ASD (Table SI-3). 
Meanwhile, the 13C T1 values for HPMC-AS in the ASDs are 
slightly increased, presumably indicating an increase in rigidity 
when formulated and suggesting its co-binding in API-polymer 
interactions (see below). In addition, 13C NMR signals for CdI/CeI 
and quaternary carbons Cfa show a small difference in chemical 





Figure 5. (a) 15N CP MAS spectra of crystalline acetaminophen form I (brown), 10% wt. (dark blue) 20% wt. (orange), and 40% wt. 
(red) acetaminophen – HPMC-AS ASDs. (b) Quantitative 1H spectra of crystalline acetaminophen form I (brown), HPMC-AS (black), 
10% wt. (dark blue), 20% wt. (orange), and 40% wt. (red) acetaminophen HPMC-AS ASDs after recrystallisation. 1H signals assign-
ment is based on the 13C and 15N CP HETCOR experiments in Figure 6(a) and Figure SI-5, respectively. Magnified views of both 15N 
CP and 1H spectra can be found in Figure SI-6 and SI-7, respectively. 
suggests structural change in the amorphous systems43,45,70 
attributed to crystalline API conversion to its amorphous 
form71 and results from the absence of long-range 3D 
interactions (e.g., hydrogen-bonding, π-π interactions) in the 
crystalline sample, resulting in variation of local electronic 
environments. 
Furthermore, and more importantly, the carbonyl carbons of 
the A and S units (C15,18 and C13) in the ASDs appear to be 
sensitive to the amount of amorphous acetaminophen in the 
ASDs as a slight change in chemical shifts vs. HPMC-AS to higher 
frequency is observed (Figure 4(b) and Table 1), as shown by 
the deconvoluted signals for the 190–160 ppm region of the 
spectra that assumed the presence of three carbonyl signals Cb, 
C13,15 and C18, “three signals model” and supported by residual 
spectra (Figure SI-4). These shifts are ascribed to API - polymer 
intramolecular interaction in ASDs and detect molecular 
association via H-bonding in dispersions,31,72,73 as previously 
observed in the Posaconazole (POSA) and HPMC-AS ASD.44 
The 13C CP MAS NMR spectrum of the 40% wt. ASD was also 
recorded after 1 week under ambient condition (Figure 4(c)) 
and shows significant differences with the one obtained at less 
than 1 day at RT/ambient RH. The spectrum exhibits a number 
of additional and sharper peaks as well as a lengthening of the 
1H T1’s (Table SI-4) indicating the presence of crystalline 
acetaminophen arising from fast recrystallisation from the 
ASDs. The resonances observed in Figure 4(c) (a magnified 
view of this spectrum is given in the aromatic region is given in 
Figure SI-3) indicates the presence of signals that can be 
attributed to both acetaminophen form I (Figure 4(a), brown) 
and II68 as anticipated from the PXRD data (Figure 2). The 
 
Table 2. Experimental 15N isotropic chemical shifts 
iso(15N), 14N shifts iso(14N), 14N quadrupolar-induced 
shifts δiso
Q
 and quadrupolar products PQ.  





-244 -125 119 2.5 
10% wt. ASD c -247 -75 172 2.9 
20% wt. ASD d -247 -80 167 2.9 
Recrystallised  
40% wt. ASD c 
-243 -67 176 2.9 
a Shifts are given in ppm. iso(15N) values are obtained from the 
peak positions in the 15N CP MAS spectra (with an associated 
error of ± 1 ppm) while iso(14N) values represent the centre of 
gravity of the 14N line shape extracted from the 14N-1H HMQC 
spectra (with an associated error of ± 5 ppm). Magnetic field 
dependent 14N shifts quoted in the table are given for 20 T. b PQ 
values are given in MHz, with an estimated error of ± 0.1 MHz, 
and obtained from Eq. 5. c Experimental data obtained at 20 T. 
d Experimental data obtained at 18.8 T (Table SI-5) and quoted 
at 20 T. 
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presence of signals attributable to the two polymorphs of 
acetaminophen in 40% wt. ASD strongly indicates the 
instability of this dispersion towards recrystallisation and 
could be reasonably explained by the lack of any interaction 
between acetaminophen and HPMC-AS, as predicted by the 
significant negative deviation from the GT model (Figure 1). 
Figure 5(a) compares the 15N CP MAS NMR spectra of 
acetaminophen form I, 10% wt. and 20% wt. amorphous 
acetaminophen in HPMC-AS solid dispersion which show one 
signal assignable to the acetaminophen NH amide group 
(Figure 1(a)). This peak resonates at -243 ppm and is fairly 
narrow (full-width-at-half maximum, FWHM of 26 Hz) which is 
consistent with the literature data for acetaminophen form I68, 
while the signal appears at -247 ppm for both 10% wt. and 20% 
wt. ASDs and is significantly broader (FWHM of 240-260 Hz). 
The change in the 15N chemical shift and broadening of the 15N 
spectra observed between crystalline and amorphous species 
suggests a different hydrogen-bonding network and 
intramolecular interactions (Table 2).42,45,74 The 15N CP 
spectrum of the 40% wt. ASD shows a single resonance at -243 
ppm (FWHM of 24 Hz) at the same chemical shift for crystalline 
form I and likely arises from acetaminophen that underwent 
recrystallisation during data acquisition. Although 
acetaminophen forms I and II in the 40% wt. ASD have been 
observed in both PXRD and 13C NMR data, the two expected 15N 
signals are not resolved at 9.4 T, likely due to their very similar 
chemical shift values only separated by 0.4 ppm.68 
The 1H MAS NMR spectrum (Figure 5(b)) of acetaminophen 
form I, obtained under high magnetic field (> 18.8 T) and very 
fast MAS frequency (> 50 kHz), shows fairly resolved 
resonances at around 9.0, 7.9, 6.7, 5.7 and 1.1 ppm assigned to 
-NH and -OH groups, aromatic protons (HdI and HeI) and methyl 
groups, respectively. In the HPMC-AS spectrum, the three main 
peaks, and the peak at 1.1 ppm can be assigned to H1, H2,3,5,10, 
H16,17, and H11,14, respectively, while spectral deconvolution 
reveals additional signals at 3.9, 3.0, and 2.5 ppm that are 
assigned to H6,9, H8, and H4, respectively. Due to possible 
exchange phenomena, the H7, -OH (hydroxypropyl substituent 
group) and the -CO2H (succinoyl moiety) proton signals (Figure 
1) are not observed in the 1D and 13C CP HETCOR spectra. 
The 1H spectra of HPMC-AS and all three ASDs (Figure 5(b)) are 
assigned from correlations observed in the 13C CP HETCOR 
spectra recorded at a short contact time (Figures 6(a)), 15N CP 
HETCOR spectrum of the 20%wt (Figure SI-5) and known 1H 
chemical shifts. The 1H spectra of the ASDs (Figure 5(b)) show 
a cluster of signals around 5 and 1 ppm, corresponding HPMC-
AS, as well as additional resonances for the acetaminophen. As 
summarised in Table 3, in the 10% wt. and 20% wt. ASDs, the 
aromatic proton signals (Hda and Hea) are deshielded with 
respect the crystalline counterpart, the small difference 
observed being typical of amorphisation processes.71 Finally, 
the Hga and Hha signals merged into a single broad signal 
centred at 8.5 ppm which correlates strongly with the 15N 
signal as revealed by the 15N CP HETCOR spectrum (Figure SI- 
5), potentially confirming the absence of deprotonation. It has 
been demonstrated that deprotonation effect, promoted by the 
solvent during the spray dry process, might impact API- 
polymer interactions.45 It is well known that evaluation of the 
length scale of spin diffusion allows the degree of mixture 
miscibility to be determined by recording the 1H relaxation 
times of all components.75–78 1H T1 and T1ρ values have 
 
Table 3. Significant changes observed in 1H chemical 









40% wt. ASD 
Hh 9.0 8.5 8.5 9.0 (I/II) 
Hg 7.9 8.5 8.5 7.9 (I/II) 
Hd 6.7 7.4 7.4 7.2 (I/II), 5.7 (I/II) 
He 5.7 6.8 6.8 6.8 (II), 5.7 (I) 
a Values are given in ppm. A comprehensive list of 1H chemical 
shifts can be found in Table SI-7. The associated error with the 
chemical shift values is ± 0.2 ppm. 
therefore been measured for the API and polymer in the ASD 
(Tables SI-4 and SI-6) and revealed that, for the 20% wt. 
formulation, they are similar (e.g., 1H T1 values for Hda and H1 
are 1.7 ± 0.2 s and 1.9 ± 0.3 s, respectively, and 1H T1ρ (Hda) = 
3.8 ± 1.1 ms ≈ 1H T1ρ (H1) = 4.4 ± 0.3 ms at a spin lock frequency 
of 40 kHz), indicating, that in the 2-5 nm length scale,79 there is 
miscibility in the acetaminophen – HPMC-AS ASD. In contrast, 
significantly different 1H T1 and T1ρ values are obtained for the 
recrystallised 40% wt. dispersion (Table SI-6) suggesting that 
phase separation phenomena occur in a domain size larger that 
20 – 50 nm.79 
Through space 13C CP HETCOR experiments recorded at a 
longer contact time (in the range of ms) allows observation of 
acetaminophen-polymer interactions with correlation signals 
providing direct evidence of intermolecular drug polymer 
interactions. The corresponding 13C CP HETCOR spectra of both 
10% wt. and 20% wt. ASD identified correlation signals 
between peaks in 13C at 120-150 ppm corresponding to 
acetaminophen with 1H at 3 ppm (shaded signals in Figure 
6(b)). These spatial correlations, detected via the strong 13C-1H 
heteronuclear dipolar coupling due to the rigid protons on the 
cellulose ring, cannot be ascribed to intramolecular 
correlations within acetaminophen due to the absence of 1H 
signals at this shift (Figure 5(b)), but rather intermolecular 
acetaminophen – HPMC-AS interaction involving the aromatic 
carbons of acetaminophen with the backbone cellulose ring’s 
protons of the polymer.  
In sharp contrast, the 13C CP HETCOR spectrum of 40% wt. ASD 
identifies correlated signals corresponding to crystalline 
acetaminophen interacting with itself as shown by the shaded 
signals in Figure 6(b) (no 2D correlation is observed for the 
broader shoulders of the 1D spectrum likely due to poor signal-
to-noise ratio in the HETCOR of the minor amorphous 
acetaminophen species). This suggests the absence of 
acetaminophen – HPMC-AS intramolecular interaction and 
indicates a two-phase immiscible system in which API-API 
interactions dominate, in good agreement with GT predictions, 
the presence of acetaminophen recrystallisation and validating 
1H relaxation data (see above), thereby confirm the instability 
of this ASD at the atomic level. 
14N-1H HMQC experiments were then deployed under optima 
conditions of high magnetic field and very fast MAS frequency 
to establish the involvement of the amide nitrogen in the 
intermolecular interactions in these ASDs. 14N is a high 
abundance spin (99.6 %) but due to its low gyromagnetic ratio 
(1.93 ×107 rad T-1 s-1) and spin quantum number I = 1, 14N has 
low sensitivity and exhibits quadrupole interaction, leading to 





Figure 6. 13C CP HETCOR spectra of HPMC-AS (black), 10% wt. (dark blue), 20% wt. (orange) and 40% wt. (red) acetaminophen 
HPMC-AS ASD recorded with a contact time of (a) 50 μs and (b) 2 ms. Correlations were used for 1H spectral assignments. Top: 13C 
CP MAS spectra at a contact time of 2 ms. Left: 1H MAS NMR spectra. Internal projections are shown in dotted lines. The 13C CP MAS 
NMR spectrum of acetaminophen form I is also given (brown). In panel (a) the dashed lines are used to highlight correlations used 
for 1H assignment. For clarity, the correlation peaks for the polymer are only highlighted for the polymer’s HETCOR in panel (a, 
black). In panel (b) the dashed lines denotate the carbon signal involved in API-polymer interaction, or API-API interaction for the 
40% wt. dispersion while the shaded sections in the spectra mark the cross correlation peaks that shown the API-polymer interac-






Figure 7. 14N-1H HMQC experiments of 10% wt. (dark blue), 20% wt. (orange) and 40% wt. (red) acetaminophen HPMC-AS ASDs 
obtained at a MAS frequency of 60 kHz. Data for 10/40% and 20% wt. were collected at 20 T and 18.8 T, respectively. Spectra were 
recorded with recoupling times of 133.6 μs (10% wt. ASD, 8 rotor periods), 66.8 μs (20 % wt. ASD, 4 rotor periods) and 801.6 μs 
(40% wt. ASD, 48 rotor periods). The deconvoluted 1H spectra of HPMC-AS under the same condition is also given in black. Spectra 
on the left of the 2D HMQC are the 14N slices extracted at the indicated 1H chemical shifts in dashed black lines.  
detection of the 14N signal in the solid-state represents a 
challenge. The development of indirectly detected 14N via 1H as 
for example via 2D 14N-1H HMQC experiments at high magnetic 
field and very fast MAS frequency has enabled to solve this 
challenge, establishing this approach as a promising 
methodology for identifying H-bonding between components 
in pharmaceutical systems.51,52,80. The corresponding 14N-1H 
HMQC experiments for the 10% wt. and 20% wt. ASDs (Figure 
7) identify the presence of correlation between the 
acetaminophen 14Na signal with the -OCH3 methoxy group (H8) 
of the polymer at 3 ppm and highlights H-bonding between this 
amide donor and oxygen acceptor. In the spectra, no 
correlation between the NH group of paracetamol and the 
protons of the substituent groups P, A, and S (Figure 1) were 
identified, thus excluding the involvement of these groups in 
the formation of the H-bond between API -polymer. 
Importantly, this 14N signal correlating with H8 does not 
correspond to same proton (Hha) identified via 15N CP HECTOR 
that established the NH correlation within acetaminophen 
(Figure SI-5) and suggests longer range interactions. We note 
that this interaction for the 10% wt. and 20% wt. amorphous 
dispersions was identified using short recoupling times of 
133.6 and 66.8 µs, respectively, suggesting a closer contact 
between acetaminophen and HPMC-AS in those systems than 
in crystalline acetaminophen, which is consistent with 
previous work in amorphous formulation.52 It is proposed that 
this H-bonding interaction is dominant in order to stabilise 
acetaminophen in its amorphous form in these ASDs. 
In contrast to the 10% wt. and 20% wt. ASDs, the 14N-1H HMQC 
spectrum for the 40% wt. ASD clearly exhibits correlations 
between the 14N and 1H (HhI/II, HeII/HdI/II and HaI/II) signals 
within acetaminophen and no correlation to the HPMC-AS 
polymer, confirming the absence of acetaminophen – HPMC-AS 
interactions at this high drug loading. The API-API H-bonding 
interaction was found at significantly longer recoupling times 
reasonably indicating a longer distance between the packed 
acetaminophen molecules in the crystal structure when 
compared the API-polymer distance in amorphous systems as 
illustrated previously.50 For both the 10% wt. and 20% wt. 
amorphous dispersions, the correlation signals in the 13C CP 
HETCOR experiments carried out at long contact times (Figure 
6(b)) and 14N-1H HMQC spectra (Figure 7) highlight 
intermolecular amorphous drug-polymer H-bonding 
interactions (Figure 8).  
 
 
Figure 8. A schematic representation of the interactions that 
have been experimentally identified in this work. For 
dispersions with a drug loading of < 20% wt., spatial proximity 
(---) and H-bond (≣) were identified between the API and the 
polymer. The acetaminophen and HPMC-AS molecules are 
given in light blue and black, respectively. 
 
The experimental 14N shifts for the observed signals in Figure 
7 and the 15N isotropic chemical shifts obtained in the 15N CP 
experiments (Figure 5(a)) for the 10% wt. and 20% wt. ASDs 
are listed in Table 2. The differences in shifts between 14N and 
15N are due to the 14N isotropic second-order quadrupolar shift 




( N14 ) =  δiso( N
14 ) −  δiso( N
15 )   (3) 
and allows the determination of the quadrupolar product PQ 
















where 0 is the 14N Larmor frequency. PQ depends on the 
quadrupolar coupling constant CQ and asymmetry parameter 








Significant difference of around 180-190 ppm between 15N 
isotropic chemical shift and 14N shift is observed (Table 2) in 
the acetaminophen HPMC-AS ASD. This is attributed to the 
isotropic second order quadrupolar shift being sensitive to the 
presence of the H-bond as previously observed in the 50% wt. 
acetaminophen-PVP solid dispersion that extracted a δiso
Q
(14N) 
value of around 184 ppm.51 This data further supports the 
presence of acetaminophen HPMC-AS H-bond in the 
dispersions with drug loading < 20% wt and acetaminophen-
acetaminophen H-bond interaction in the recrystallised 40% 
ASD. 
These are stabilising interactions that can be imputed in the 
understanding of the stability the amorphous acetaminophen – 
HPMC-AS solid dispersions. Interestingly, the main stabilising 
interaction that has been identified in this work is H-bonding 
between the acetaminophen’s amide group with the OCH3 
proton (H8) of the HPMC-AS methyl substituent (M), likely due 
to the small steric hindrance of this substituent vs. the others 
(Figure 1). This is an unexpected finding given that the acetyl 
and succinoyl groups in HPMC-AS have been previously 
suggested to be responsible for the formation of API-polymer 




Molecular interactions in acetaminophen – HPMC-AS solid 
dispersion at 10%, 20% and 40% wt. drug loadings were 
identified by combining time-dependent PXRD with 
multidimensional multinuclear NMR experiments. The 
presence of chemical shift differences in 1D 1H, 13C and 15N CP 
MAS NMR spectra between crystalline and amorphous 
acetaminophen suggests a strong structural perturbation in the 
amorphous species, and can be potentially rationalised by the 
presence of H-bonding interactions between acetaminophen 
and the polymer. 13C CP HETCOR exploiting strong 13C-1H 
dipolar coupling highlighted spatial interaction between the 
acetaminophen’s aromatic protons with the polymer’s 
cellulose ring protons in the 10% wt. and 20% wt. ASDs. This 
interaction was further unequivocally confirmed by 14N-1H 
HMQC experiments that identify H-bond interactions between 
the NH of acetaminophen and the OCH3 proton of the HPMC-AS 
methyl substituent. The presence of this type of drug/polymer 
interaction in amorphous systems is of crucial importance as it 
stabilises the amorphous dispersions. No acetaminophen - 
HPMC-AS interactions were found in the 40% wt. dispersion, 
further validated from 1H relaxation data, indicating the 
instability of this system and its tendency to recrystallise on a 
short timescale.  
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